Lai, M.C., Lombardo, M.V. & Baron-Cohen, S. Autism. Lancet 383, 896–910 (2014).
Robinson, E.B. et al. Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population. Nat. Genet. 48, 552–555 (2016).
Anagnostou, E. et al. Autism spectrum disorder: advances in evidence-based practice. CMAJ 186, 509–519 (2014).
Carter, M.T. & Scherer, S.W. Autism spectrum disorder in the genetics clinic: a review. Clin. Genet. 83, 399–407 (2013).
Miles, J.H. Complex autism spectrum disorders and cutting-edge molecular diagnostic tests. J. Am. Med. Assoc. 314, 879–880 (2015).
Bourgeron, T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. Neurosci. 16, 551–563 (2015).
de la Torre-Ubieta, L., Won, H., Stein, J.L. & Geschwind, D.H. Advancing the understanding of autism disease mechanisms through genetics. Nat. Med. 22, 345–361 (2016).
Scherer, S.W. & Dawson, G. Risk factors for autism: translating genomic discoveries into diagnostics. Hum. Genet. 130, 123–148 (2011).
Tammimies, K. et al. Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder. J. Am. Med. Assoc. 314, 895–903 (2015).
Betancur, C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res. 1380, 42–77 (2011).
Szatmari, P. et al. Autism Genome Project. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat. Genet. 39, 319–328 (2007).
Leblond, C.S. et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 10, e1004580 (2014).
Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216–221 (2014).
Jiang, Y.H. et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am. J. Hum. Genet. 93, 249–263 (2013).
Marshall, C.R. et al. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 82, 477–488 (2008).
Miller, D.T. et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am. J. Hum. Genet. 86, 749–764 (2010).
Pinto, D. et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 94, 677–694 (2014).
Yuen, R.K. et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat. Med. 21, 185–191 (2015).
Sahin, M. & Sur, M. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science 350, aab3897 (2015).
Stavropoulos, D.J. et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPJ Genome Med 1, 15012 (2016).
Yuen, R.K. et al. Genome-wide characteristics of de novo mutations in autism. NPJ Genome Med. 1, 160271–1602710 (2016).
Buxbaum, J.D. et al. The autism sequencing consortium: large-scale, high-throughput sequencing in autism spectrum disorders. Neuron 76, 1052–1056 (2012).
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).
Sanders, S.J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. Neuron 87, 1215–1233 (2015).
Leblond, C.S. et al. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 8, e1002521 (2012).
Talkowski, M.E. et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 149, 525–537 (2012).
Noor, A. et al. Disruption at the PTCHD1 locus on xp22.11 in autism spectrum disorder and intellectual disability. Sci. Transl. Med. 2, 49ra68 (2010).
Xiong, H.Y. et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science 347, 1254806 (2015).
Anney, R. et al. Individual common variants exert weak effects on the risk for autism spectrum disorders. Hum. Mol. Genet. 21, 4781–4792 (2012).
Glazer, D. Atoms, bits, and cells. Appl. Transl. Genomics 6, 11–14 (2015).
Global Alliance for Genomics and Health. GENOMICS. A federated ecosystem for sharing genomic, clinical data. Science 352, 1278–1280 (2016).
Stein, L.D. The case for cloud computing in genome informatics. Genome Biol. 11, 207 (2010).
An, J.Y. et al. Towards a molecular characterization of autism spectrum disorders: an exome sequencing and systems approach. Transl. Psychiatry 4, e394 (2014).
Kong, A. et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 488, 471–475 (2012).
Michaelson, J.J. et al. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell 151, 1431–1442 (2012).
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
Richards, C.S. et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet. Med. 10, 294–300 (2008).
Utami, K.H. et al. Impaired development of neural-crest cell-derived organs and intellectual disability caused by MED13L haploinsufficiency. Hum. Mutat. 35, 1311–1320 (2014).
Stender, J.D. et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol. Cell 48, 28–38 (2012).
Ciernia, A.V. & LaSalle, J. The landscape of DNA methylation amid a perfect storm of autism aetiologies. Nat. Rev. Neurosci. 17, 411–423 (2016).
Sanders, S.J. et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70, 863–885 (2011).
Männik, K. et al. Copy number variations and cognitive phenotypes in unselected populations. J. Am. Med. Assoc. 313, 2044–2054 (2015).
Ameis, S.H. et al. A diffusion tensor imaging study in children with ADHD, autism spectrum disorder, OCD, and matched controls: distinct and non-distinct white matter disruption and dimensional brain-behavior relationships. Am. J. Psychiatry 173, 1213–1222 (2016).
Uddin, M. et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. Nat. Genet. 46, 742–747 (2014).
Jacquemont, S. et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature 478, 97–102 (2011).
Hadley, D. et al. The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism. Nat. Commun. 5, 4074 (2014).
Samocha, K.E. et al. A framework for the interpretation of de novo mutation in human disease. Nat. Genet. 46, 944–950 (2014).
Corominas, R. et al. Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism. Nat. Commun. 5, 3650 (2014).
Walker, S. & Scherer, S.W. Identification of candidate intergenic risk loci in autism spectrum disorder. BMC Genomics 14, 499 (2013).
Sparrow, S.S., Balla, D.A., Cicchetti, D.V., Harrison, P.L. & Doll, E.A. Vineland Adaptive Behavior Scales (American Guidance Service, 1984).
Van der Auwera, G.A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 1–33 (2013).
Pan, C. et al. Interactive analytics for very large scale genomic data. Preprint at http://biorxiv.org/content/early/2015/12/24/035295.
Merico, D. et al. Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman syndrome by disrupting minor intron splicing. Nat. Commun. 6, 8718 (2015).
Auton, A. et al. Genomes Project. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Fu, W. et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493, 216–220 (2013).
Siepel, A. et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 15, 1034–1050 (2005).
Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073–1081 (2009).
Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).
Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39, e118 (2011).
Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).
Köhler, S. et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 42, D966–D974 (2014).
Stenson, P.D. et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577–581 (2003).
Solomon, B.D., Nguyen, A.D., Bear, K.A. & Wolfsberg, T.G. Clinical genomic database. Proc. Natl. Acad. Sci. USA 110, 9851–9855 (2013).
Warde-Farley, D. et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38, W214–W220 (2010).
Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G.D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5, e13984 (2010).
Abyzov, A., Urban, A.E., Snyder, M. & Gerstein, M. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. 21, 974–984 (2011).
Zhu, M. et al. Using ERDS to infer copy-number variants in high-coverage genomes. Am. J. Hum. Genet. 91, 408–421 (2012).
Zarrei, M., MacDonald, J.R., Merico, D. & Scherer, S.W. A copy number variation map of the human genome. Nat. Rev. Genet. 16, 172–183 (2015).
Huang, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727–730 (2002).
Liu, K., Liu, Y., Lau, J.L. & Min, J. Epigenetic targets and drug discovery Part 2: histone demethylation and DNA methylation. Pharmacol. Ther. 151, 121–140 (2015).
Wagner, A.H. et al. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 44 D1036–D1044 (2016).